DE60020997T2 - Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose - Google Patents

Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose Download PDF

Info

Publication number
DE60020997T2
DE60020997T2 DE60020997T DE60020997T DE60020997T2 DE 60020997 T2 DE60020997 T2 DE 60020997T2 DE 60020997 T DE60020997 T DE 60020997T DE 60020997 T DE60020997 T DE 60020997T DE 60020997 T2 DE60020997 T2 DE 60020997T2
Authority
DE
Germany
Prior art keywords
group
peptide
receptor
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60020997T
Other languages
German (de)
English (en)
Other versions
DE60020997D1 (de
Inventor
G. Krishna PERI
Sylvain Chemtob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire Saint Justine
Original Assignee
Centre Hospitalier Universitaire Saint Justine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire Saint Justine filed Critical Centre Hospitalier Universitaire Saint Justine
Publication of DE60020997D1 publication Critical patent/DE60020997D1/de
Application granted granted Critical
Publication of DE60020997T2 publication Critical patent/DE60020997T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Water Treatment By Sorption (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pipe Accessories (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
DE60020997T 1999-12-06 2000-12-06 Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose Expired - Fee Related DE60020997T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45548399A 1999-12-06 1999-12-06
US455483 1999-12-06
PCT/CA2000/001445 WO2001042281A1 (en) 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Publications (2)

Publication Number Publication Date
DE60020997D1 DE60020997D1 (de) 2005-07-28
DE60020997T2 true DE60020997T2 (de) 2006-05-24

Family

ID=23808998

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60020997T Expired - Fee Related DE60020997T2 (de) 1999-12-06 2000-12-06 Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose

Country Status (12)

Country Link
US (1) US7442763B2 (https=)
EP (1) EP1244693B1 (https=)
JP (1) JP2003516417A (https=)
AT (1) ATE298346T1 (https=)
AU (1) AU784630B2 (https=)
CA (1) CA2396739A1 (https=)
DE (1) DE60020997T2 (https=)
ES (1) ES2246915T3 (https=)
MX (1) MXPA02005626A (https=)
NZ (1) NZ520762A (https=)
WO (1) WO2001042281A1 (https=)
ZA (1) ZA200205795B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
MXPA02005626A (es) 1999-12-06 2004-09-10 Pital Sainte Justine H Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.
EP1467738A1 (en) * 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
JP2005511562A (ja) * 2001-10-31 2005-04-28 メディカル リサーチ カウンシル 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
CN1662551A (zh) * 2002-05-23 2005-08-31 瑟瑞技术公司 前列腺素e2受体亚型ep4的拮抗肽
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
US7414029B2 (en) 2002-05-23 2008-08-19 Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US20150126573A1 (en) 2012-05-09 2015-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5508384A (en) * 1992-09-10 1996-04-16 New York University Polypeptide derived from a popamine receptor, and compositions and methods thereof
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição
US5869281A (en) 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
JPH09504174A (ja) * 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
WO1996006856A1 (en) * 1994-08-31 1996-03-07 Robert Webber Dopamine receptor peptides and anti-peptide antibodies
WO1996019233A2 (en) * 1994-12-12 1996-06-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
JPH11514207A (ja) 1995-01-25 1999-12-07 シーオーアール・セラピューティックス・インコーポレーテッド 組換えｃ１４０リセプター、そのアゴニストおよびアンタゴニスト、並びに該リセプターをコードする核酸
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
JP2001501601A (ja) * 1996-09-12 2001-02-06 メルク エンド カンパニー インコーポレーテッド 前立腺ガンの治療において有用な共役体
US5955575A (en) * 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
AUPP320998A0 (en) * 1998-04-27 1998-05-21 Walter And Eliza Hall Institute Of Medical Research, The Tyrosine phosphatase IA-2 T-cell epitopes
US6984719B1 (en) * 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
MXPA02005626A (es) 1999-12-06 2004-09-10 Pital Sainte Justine H Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.

Also Published As

Publication number Publication date
AU784630B2 (en) 2006-05-18
AU2134001A (en) 2001-06-18
EP1244693A1 (en) 2002-10-02
NZ520762A (en) 2005-02-25
US20030017988A1 (en) 2003-01-23
ATE298346T1 (de) 2005-07-15
CA2396739A1 (en) 2001-06-14
DE60020997D1 (de) 2005-07-28
EP1244693B1 (en) 2005-06-22
WO2001042281A1 (en) 2001-06-14
ZA200205795B (en) 2007-01-31
JP2003516417A (ja) 2003-05-13
MXPA02005626A (es) 2004-09-10
ES2246915T3 (es) 2006-03-01
US7442763B2 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
DE69332907T2 (de) Flk-1 ist ein rezeptor für den wachstumsfaktor der vaskularen endothelzellen
DE69635417T2 (de) VERFAHREN UND MITTEL ZUR HEMMUNG DER DURCH ALPHA v BETA 5 VERMITTELTEN ANGIOGENESE
DE69837845T2 (de) Osteoprotegerin bindende proteine und rezeptoren
DE69932510T2 (de) Vaskularisierungsinhibitoren
ES2198447T3 (es) Uso del acido 5-(tetradeciloxi)-2-furancarboxilico para el tratamiento de la enfermedad de alzheimer o la psicosis.
DE60020997T2 (de) Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose
EP0579739A1 (en) Interleukin-8 receptors and related molecules and methods
MX2007004676A (es) Analogos de la hormona adrenocorticotropica y metodos relacionados.
SI9200081A (en) Galanin antagonist
AU2003233297A2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
ES2393462T3 (es) Péptido útil para inhibir la actividad del receptor de prosta-glandina F2X
DE69428292T2 (de) Rekombinanter c140-rezeptor, seine agonisten und antagonisten
EP1255555B1 (en) NON-MAMMALIAN GnRH ANALOG AND USES THEREOF IN REGULATING FERTILITY AND PREGNANCY
DE69131355T2 (de) Die knochenresorption hemmende verbindungen und zusammensetzungen
DE69837271T2 (de) Mutanten des Thyroid-stimulierenden Hormons
JP4431280B2 (ja) Ｇタンパク質共役型受容体アゴニストまたはアンタゴニスト
JP5718649B2 (ja) Ｍｎｔｆペプチド組成物およびその使用法
DE69434118T2 (de) Klonierung und rekombinante herstellung des crf-rezeptors (crf=corticotropin ausloesefaktor)
US6984719B1 (en) Peptide antagonists of prostaglandin F2α receptor
DE69607962T2 (de) Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen
DE60125959T2 (de) Unterscheidung zwischen gnrh-i und gnrh-ii
US7414029B2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JP2000143532A (ja) 細胞増殖性疾患の環状ｒｇｄによる調節
Nguyen et al. Evidence for interplay between thyrotropin-releasing hormone (TRH) and its structural analogue pGlu-Glu-Pro-NH2 ([Glu2] TRH) in the brain: An in vivo microdialysis study
DE4342846A1 (de) Tumor-Nekrose-Faktor-alpha inaktivierende Peptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee